[1]刘朵,徐敏,顾艳,等.灯盏花素治疗血瘀型冠心病56例[J].西部中医药,2019,32(06):65-58.
　LIU Duo,XU Min,GU Yan,et al.Treating 56 Cases of Coronary Heart Disease of Blood Stasis Pattern by Breviscapine Injection[J].Western Journal of Traditional Chinese Medicine,2019,32(06):65-58.
点击复制

灯盏花素治疗血瘀型冠心病56例
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
32
期数:
2019年06期
页码:
65-58
栏目:
出版日期:
2019-06-15

文章信息/Info

Title:
Treating 56 Cases of Coronary Heart Disease of Blood Stasis Pattern by Breviscapine Injection
文章编号:
1004-6852(2019)06-0065-04
作者:
刘朵，徐敏，顾艳，高妍，钱芳△
上海市嘉定区中医医院药剂科，上海 201800
Author(s):
LIU Duo, XU Min, GU Yan, GAO Yan, QIAN Fang△
Department of Pharmacy, Jiading District TCM Hospital, Shanghai 201800, China
关键词:
灯盏花素; 冠心病; 血瘀证
Keywords:
breviscapine injection;  coronary heart disease;  blood stasis pattern
分类号:
R541.4
文献标志码:
B
摘要:
目的：研究灯盏花素在血瘀型冠心病中的应用情况。方法：回顾性分析调查灯盏花素在56例血瘀证冠状动脉粥样硬化性心脏病患者中的使用情况，包括剂量、使用时间、溶媒、联合用药等用药情况；观察患者症状积分及临床疗效、心电图改善情况、全血黏度、血浆黏度、纤维蛋白原、血浆凝血酶原时间、药物不良反应发生等情况。结果：灯盏花素日剂量为40～50 mg，平均(47.96±4.01) mg。住院期间使用灯盏花素总剂量为240～1 450 mg，平均(558.57±220.10) mg。灯盏花素溶媒：5%葡萄糖注射液2例，木糖醇注射液3例，0.9%氯化钠注射液51例。灯盏花素使用天数5～29天，平均(11.64±4.45)天。灯盏花素联合前列地尔、低分子肝素、阿司匹林、氯吡格雷分别为17例、3例、24例、4例；联合使用参麦注射液26例；联合使用中药口服汤剂共29例，28例联合活血化瘀中药。中医症状疗效，显效29例，有效25例，无效1例，加重1例，总有效率为96.43%。胸痛、胸闷、气短、心悸、神倦乏力、不寐等症状积分出入院时比较，差异有统计学意义(P＜0.05)。入院正常心电图或ST段未见明显异常患者29例，占51.79%；住院前后心电图疗效有效16例（28.57%），无效11例（19.64%）。5例药物不良反应，均为一般药物不良反应。结论：注射用灯盏花素可明显缓解患者临床症状，临床使用安全，溶媒选择合理，目前应深入研究灯盏花素与其他药物的相互作用，以及开发灯盏花素的新剂型。
Abstract:
Objective: To study the application conditions of breviscapine injection to coronary heart disease (CHD) of blood stasis pattern. Methods: The application conditions of breviscapine injection to 56 patients suffering coronary atherosclerotic heart disease of blood stasis pattern were retrospectively analyzed and investigated, including the dose, application time, the solvent, the drug combination and others; to observe the symptoms integrals, Crlrative effects, ECG improvement, whole blood viscosity, plasma viscosity, fibrinogen, plasma prothrombin time, the incidence of adverse reaction and others. Results: Daily dose of breviscapine was 40~50 mg, average (47.96±4.01)mg. Total dose of using breviscapine during hospitalization period was 240~1 450 mg, average (558.57±220.10)mg. Breviscapine solvent: two cases using 5% glucose injection, three cases using xylitol injection, 51 cases using 0.9% sodium chloride injection. Breviscapine injection was used for five to 29 days, average (11.64±4.45) days. There were 17 cases combining breviscapine injection with alprostadil, three cases combined with low molecular heparin, 24 cases with aspirin and four cases with clopidogrel respectively; 26 cases with ShenMai injection; 29 cases with herbal oral decoction, 28 cases with the herbal decoction pieces of promoting blood circulation and eliminating blood stasis. Clinical effects of the symptoms, there were 29 cases markedly effective, 25 cases effective, one case ineffective, one case aggravated, total effective rate was 96.43%. The difference had statistical meaning in the comparisons of the scores of the symptoms including chest pain and stuffiness, panting, palpitation, lassitude and fatigue, insomnia and others (P＜0.05). There were 29 cases showing normal ECG or no obvious abnormal changes in ST segments, and they held 51.79%; after hospitalization, there were 16 cases effective in clinical effects of ECG (28.57%), 11 cases ineffective (19.64%). Drug adverse reaction (DAR) happened in five patients, and they were common DAR. Conclusion: Breviscapine injection could gain notable effects in relieving the symptoms, and it shows clinical safety and rational selection of the solvents, currently, the interactions of breviscapine injection with other drugs and the development of new forms of breviscapine should be further studied.

相似文献/References:

[1]马思清 指导：谢春毅.瓜蒌薤白三方防治冠心病的研究现状[J].西部中医药,2012,25(10):118.
　MA Si-qing Director: XIE Chun-yi.Exploration on Three Pieces of GuaLou XieBaiFang in the Prevention of Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(06):118.
[2]潘雪晖.综合护理干预对冠心病患者不良生活方式的影响[J].西部中医药,2013,26(07):105.
　PAN Xuehui.Impact of Comprehensive Nursing Intervention on Lifestyles of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(06):105.
[3]袁春玲.家庭病床冠心病护理可行性探讨[J].西部中医药,2012,25(07):109.
　YUAN Chun-ling.Probe into Feasibility of Nursing for Patients with Coronary Heart Disease in Family Practice[J].Western Journal of Traditional Chinese Medicine,2012,25(06):109.
[4]王凯,林文.丹红与丹参酮ⅡA治疗冠心病心绞痛疗效比较[J].西部中医药,2013,26(08):88.
　WANG Kai,LIN Wen.Comparison between DanHong Injection and Tanshinone ⅡA in Treating Angina Pectoris of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(06):88.
[5]赵云霞,刘正跃.综合护理干预对冠心病患者不良生活方式的影响[J].西部中医药,2012,25(05):105.
　ZHAO Yun-xia,LIU Zheng-yue.Effects of Comprehensive Nursing Intervention on Unhealthy Lifestyle of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(06):105.
[6]王瑞福.调脂汤对冠心病PCI术后血液流变学及血脂的影响[J].西部中医药,2013,26(12):71.
　WANG Ruifu.Effects of TiaoZhi Tang on Blood Lipid and Rheology of the Patients with Coronary Heart Disease After PCI[J].Western Journal of Traditional Chinese Medicine,2013,26(06):71.
[7]孙文,谢春毅△.丹红注射液治疗冠心病心绞痛临床观察[J].西部中医药,2014,27(03):5.
　SUN Wen,XIE Chunyi.Clinical Observation on DanHong Injection in Treating Coronary Heart Disease Angina Pectoris[J].Western Journal of Traditional Chinese Medicine,2014,27(06):5.
[8]付伟光,齐振勇,李爱军,等.HCY、HS-CRP、LP(a)及 D- 二聚体联合检测在冠心病病程中动态检测意义的研究*[J].西部中医药,2014,27(08):148.
[9]张丽君,赵江花,赵海红,等.心脉疏膏穴位贴敷结合西药治疗冠心病心绞痛 40 例[J].西部中医药,2014,27(09):128.
[10]张红丽,刘海荣△,王媛,等.综合护理对老年冠心病心绞痛患者生活质量的影响[J].西部中医药,2014,27(10):143.

备注/Memo

备注/Memo:
收稿日期：2018-10-27*基金项目：上海市嘉定区中医医院院级课题(编号2014-04)。作者简介：刘朵(1987—)，女，硕士学位，主管中药师。研究方向：临床药学。△通讯作者：钱芳(1973—)，女，硕士学位，副主任药师。研究方向：临床药学。
更新日期/Last Update: 2019-06-15